Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Wedbush was dead wrong on their call & PATH PPS will be bouncing around $2 for some time to come.
NuPathe PATH Wedbush Outperform $20
http://www.breifing.com/investor/calendars/upgrades-downgrades/
I am in - 5,000 @ $2.05. In hindsight, the funding deal [NuPathe Inc Announces Common Stock Purchase Agreement For Up To $30 Million - http://www.reuters.com/finance/stocks/PATH.O/key-developments/article/2376047 ] was smart. I almost stepped in earlier, but I have a problem with the CEO salary. I feel confident for a profit from this level. This is critical to their entire existent (platform). the PR telegraphed that a phase 1 trial would be adequate, but is that the FDA opinion! I am skeptical. Regardless, they will try very hard for approval and as a consequence an increased pps.
PATH 2.10$ Wedbush Lowers PT on NuPathe from 20$ to 17$ and maintains its Outperform rating.
Could of been worse. It could of dropped from a higher pps. Like it's high of 8.74. I hope no one held on from those levels.
Well it looks like I chose the wrong PATH! Now I wonder how low it will go??
Sho-Nuff
Sorry guys! You win some and lose some.. I'm waiting for a bigger dip.
UPDATE 1-FDA rejects NuPathe's migraine patch
Tue Aug 30, 2011 7:02am EDT
* Co says may need to do additional trials
* FDA raises issues related to manufacturing, safety
Aug 30 (Reuters) - NuPathe Inc said the U.S. health regulator rejected its experimental migraine patch and the company may need to conduct additional trials to address the issues raised by regulators.
In a complete response letter to the company, the U.S. Food and Drug Administration raised questions related to the chemistry, manufacturing and safety of the treatment, known as Zelrix, the company said in a statement.
NuPathe believes it has, or shortly will have, sufficient data to address the issues and may conduct additional early-stage and/or non-clinical studies to address other questions.
The company will also request a meeting with the FDA to discuss the letter and its approach to resolve the issues.
Migraine is a neurological disorder that affects about 30 million adults in the United States, NuPathe said.
Shares of the company closed at $4.05 on Monday on Nasdaq. (Reporting by Esha Dey in Bangalore; Editing by Roshni Menon)
FDA Requests Additional Information Regarding NuPathe's Migraine Patch in Complete Response Letter
http://finance.yahoo.com/news/FDA-Requests-Additional-iw-1874063175.html?x=0
Again, my guess is that PATH had a no from the FDA review. Maybe they are trying to get more detail from the FDA, but they will almost have to release what came from the FDA prior to pre-market trading or the company will come up against other issues. Unless they continue the halt.
http://www.nasdaqtrader.com/Trader.aspx?id=Tradehalts
T1 Halt - News Pending
Trading is halted pending the release of material news.
True, but why would they halt the stock so early then?
All the posting today in regards to the scheduled FDA review for today, first is someone sure that it took place today? If it did take place today, then the lack of PR from PATH would lead me to believe it was a no from the FDA.
(the east coast storm could have changed the meeting time)
Investor666 Brian
Just got the same response from Sandy Walsh from the FDA "Check with the Company" regarding $PATH
Actually
You should check with the company for an update.
I'm not that crazy! I only put about $500 into it. All I really had to spare. I wasn't about to use my margin balance for leverage. Too risky!
If it tanks I ain't losing much so I'll hold. On the other hand if I can make a quick $200 to $500 on approval I'll take it.
hello :)
you know what?
that was excatly what i thought about it at first...i had 500 shares holding (but sold) ...
btw, its taking time...
That's the way it's supposed to happen. But with DRRX and PTIE is was trading in the pre-market hours before the PR where of course it tanked. That being because I got the word of the CRL from the FDA on the previous evening which was posted (Gekko and AF actually posted the news) on Twitter.
I had been in contact with both Geoffrey (Gekkowire)and Adam and they got the news also from the FDA after I did.
I have an order in for $1.00 just in case. I have a small amount so if it's not approved I'll average down and hold. Maybe make a few bucks off the dollar shares if it executes.
So PATH is halted because PATH has word from the FDA, but PATH is not giving us the information yet?????
Will PATH remain halted until they give the PR update then? This is my first biotech play to hold through for a decision. Once they give the PR how long afterward will they remain halted?
Thanks,
Sho-Nuff
No word from the FDA. They say check with the company. This is a long halt. Doesn't look good! But we are talking about the FDA.
So it doesn't even look like we are going to get a PR today. How long after we get the PR will trading stay halted??
Thanks,
Sho-Nuff
When will this dice stop!
you see... i don't own any more shares here ...but everyday i placed my buy order at $1.50 in case of bear-raid ...never happened, though...oh, well...
and now i'm hoping for the BEST for you and path longs!
I was thinking we would have heard something by now!!
JMO,
Sho-Nuff
Looks like they might be going for AH
Can't say I really like that.
My old daddy used to say..."son, it always looks the darkest, right before it turns completely f#%$# black. Dad, never made any money giving motivational speeches.
Everything I have seen says 90% chance of approval...lets roll the dice
Halted, but where's the news. Silence before the big storm!
kookie I like that link. thanks
Thanks for the link. Trying not to hold my breath waiting on the news. Trying to breathe normally!!
I sure hope I am on the right PATH!!
JMO,
Sho-Nuff
think or swimm news feed, ck out your real time.
Here is the link to all current trading halts including PATH
http://www.nasdaqtrader.com/Trader.aspx?id=Tradehalts
Yes if it can fundamentally affect the trading one way or the other.
invest2win Anything from your Investors on Twitter ??
It is not abnormal
Is that normal for them to halt trading for the NEWS on these types of stocks?
Sho-Nuff
Let's see what happens.
Halted pending news
Well, I am there also....to late now, we can either sell at the present PPS or roll the dice
I sure hope I chose the right PATH with this one!!!
Maybe we will get the news AH today! I hope it does a PPS good!
JMO,
Sho-Nuff
Like the action today.
My opinion, and read my sig, is that we will hear after market closure.
I wish PATH would hurry up and tell us the news!!
JMO,
Sho-Nuff
I keep staying glued to the computer waiting for something from PATH one way or the other!
Sho-Nuff
I don't try to predict prices; it is what it is, play it accordingly.
I have been so wrong so many times... SPPI actually tanked on approval...AMRN doubled...PLX got a CRL and tanked 50%...its like Vegas...lets roll the dice, already down so lets go
I was hoping to see something this morning PM, but that chance is quickly coming to an end. I guess AM is the most probable time to hear something now?
Any predictions on the PPS if:
They do get approved...
They do not get approved...
Thanks,
Sho-Nuff
No telling w/FDA.
Is that good or bad at this point? Waiting until the day of... does that give us any insight as to what will happen?
Thanks,
Sho-Nuff
Haven't seen anything yet.
Followers
|
36
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
724
|
Created
|
10/07/10
|
Type
|
Free
|
Moderators |
Our first commercial product is Zecuity™ sumatriptan iontophoretic transdermal system (patch) for the acute treatment of migraine. We are seeking commercialization partners in the U.S. and worldwide.
In addition, we have a strong pipeline based on our biodegradable implant technology that allows us to deliver therapeutic levels of medication over a period of months with a single dose. NP201, for the continuous symptomatic treatment of Parkinson's disease, utilizes a leading FDA-approved dopamine agonist and is being developed to provide up to two months of continuous delivery. NP202 is being developed to address patient noncompliance, a long-standing problem in the treatment of schizophrenia and bipolar disorder, by providing three months of continuous delivery of risperidone, an atypical antipsychotic. We are seeking a development partner for each of these candidates to capitalize on their commercial potential worldwide.
Beyond our current product pipeline, we intend to be a leader in the rapidly growing transdermal patch market with our active SmartRelief technology, delivering innovative solutions across a range of therapeutic areas.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |